New drug DNTH103 aims to tame muscle weakness in myasthenia gravis
NCT ID NCT06282159
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 study tests a drug called DNTH103 (claseprubart) in 65 adults with generalized myasthenia gravis, a condition that causes muscle weakness. Participants receive either the drug or a placebo, first through an IV and then as injections under the skin every two weeks for 11 weeks. The goal is to see if the drug is safe and can improve daily activities like talking, swallowing, and moving.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Claseprubart (also called DNTH103), a drug given by IV and then injections under the skin
What this could lead to
If it works, this could point toward a new treatment option to control symptoms of generalized myasthenia gravis.
What could go wrong
This is an early Phase 2 trial with only 65 people, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS, GENERALIZED are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clincal Study Site
Tampa, Florida, 33620, United States
-
Clinical Study Site
Phoenix, Arizona, 85028, United States
-
Clinical Study Site
Irvine, California, 92868, United States
-
Clinical Study Site
Stamford, Connecticut, 06905, United States
-
Clinical Study Site
Boca Raton, Florida, 33487, United States
-
Clinical Study Site
Bradenton, Florida, 34205, United States
-
Clinical Study Site
Maitland, Florida, 32751, United States
-
Clinical Study Site
O'Fallon, Illinois, 62269, United States
-
Clinical Study Site
Kansas City, Kansas, 66103, United States
-
Clinical Study Site
Lexington, Kentucky, 40503, United States
-
Clinical Study Site
Boston, Massachusetts, 02215, United States
-
Clinical Study Site
East Lansing, Michigan, 48824, United States
-
Clinical Study Site
Columbia, Missouri, 65212, United States
-
Clinical Study Site
Cincinnati, Ohio, 45219, United States
-
Clinical Study Site
Columbus, Ohio, 43221, United States
-
Clinical Study Site
Dallas, Texas, 75206, United States
-
Clinical Study Site
Dallas, Texas, 75243, United States
-
Clinical Study Site
Houston, Texas, 77030, United States
-
Clinical Study Site
Lubbock, Texas, 79414, United States
-
Clinical Study Site
Richmond, Virginia, 23219, United States
-
Clinical Study Site
San Miguel de Tucumán, Tucumán Province, T4000, Argentina
-
Clinical Study Site
Buenos Aires, 20/11/1902, Argentina
-
Clinical Study Site
Buenos Aires, C1012AAR, Argentina
-
Clinical Study Site
Buenos Aires, C1015ABR, Argentina
-
Clinical Study Site
Córdoba, X5004CDT, Argentina
-
Clinical Study Site
Rosario, 2000, Argentina
-
Clinical Study Site
London, Ontario, N6A 5W9, Canada
-
Clinical Study Site
Ostrava, 70852, Czechia
-
Clinical Study Site
Copenhagen, 02100, Denmark
-
Clinical Study Site
Bordeaux, 33076, France
-
Clinical Study Site
Nice, 06001, France
-
Clinical Study Site
Strasbourg, 67000, France
-
Clinical Study Site
Haifa, 3109601, Israel
-
Clinical Study Site
Ramat Gan, Israel
-
Clinical Study Site
Safed, 13100, Israel
-
Clinical Study Site
Milan, 20133, Italy
-
Clinical Study Site
Naples, 80131, Italy
-
Clinical Study Site
Pisa, 56126, Italy
-
Clinical Study Site
Rome, 00168, Italy
-
Clinical Study Site
Rome, 00189, Italy
-
Clinical Study Site
Amsterdam, Netherlands
-
Clinical Study Site
Skopje, 1000, North Macedonia
-
Clinical Study Site
Bergen, 5021, Norway
-
Clinical Study Site
Bydgoszcz, 85-065, Poland
-
Clinical Study Site
Katowice, 40123, Poland
-
Clinical Study Site
Krakow, 31-202, Poland
-
Clinical Study Site
Krakow, 31-503, Poland
-
Clinical Study Site
Lublin, 20-093, Poland
-
Clinical Study Site
Warsaw, 01-684, Poland
-
Clinical Study Site
Warsaw, 02-657, Poland
-
Clinical Study Site
Belgrade, 11000, Serbia
-
Clinical Study Site
Kragujevac, 34000, Serbia
-
Clinical Study Site
Niš, 18000, Serbia
-
Clinical Study Site
Novi Sad, 21000, Serbia
-
Clinical Study Site
Malmö, Sweden
-
Clinical Study Site #2
Houston, Texas, 77030, United States